Related Experiment Video
Updated: Jun 4, 2026
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
Primary aldosteronism: A contrarian view.
1University of Texas Southwestern Medical School, Dallas, TX 75390, USA. Norman.Kaplan@UTSouthwestern.edu
Reviews in Endocrine & Metabolic Disorders
|February 12, 2011
Summary
Primary aldosteronism (PA) may be less common than presumed due to diagnostic uncertainty. Current diagnostic methods lack validated accuracy, complicating prevalence assessment and potentially overestimating the need for extensive testing.
Area of Science:
- Endocrinology
- Internal Medicine
- Clinical Diagnostics
Background:
- Primary aldosteronism (PA) is a significant cause of secondary hypertension.
- Accurate prevalence data for PA is crucial for clinical management and public health.
- Existing diagnostic protocols for PA are debated regarding their validity and effectiveness.
Purpose of the Study:
- To critically evaluate the current understanding of primary aldosteronism prevalence.
- To question the reliability of diagnostic procedures used for PA detection.
- To propose a more pragmatic approach to PA management.
Main Methods:
- Review of existing literature on primary aldosteronism diagnosis and prevalence.
- Analysis of the validity and limitations of current diagnostic techniques.
- Discussion of the implications for clinical practice and patient management.
Main Results:
- Evidence suggests primary aldosteronism is likely less common than widely believed.
- Significant uncertainties exist regarding the validity of all diagnostic procedures for PA.
- The true prevalence of PA cannot be reliably determined with current methods.
Conclusions:
- The actual prevalence of primary aldosteronism remains uncertain due to diagnostic limitations.
- Overestimation of PA prevalence may lead to unnecessary extensive testing and costs.
- Simplified diagnostic and treatment pathways for PA may be feasible and cost-effective.
Related Concept Videos
01:27Adrenal Gland Disorders
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...